Icatibant Accord (Icatibant)

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are the primary mechanisms driving the swelling seen in hereditary angioedema.

The dose and administration schedule are determined by the prescribing clinician based on the patient’s condition and response. Icatibant is administered as a subcutaneous injection, and the exact amount is individualized for each acute HAE episode.

Safety data for Icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

The main alternative class for HAE is plasma‑derived or recombinant C1‑esterase inhibitors, which replace the deficient protein. Icatibant, by contrast, blocks the bradykinin B2 receptor directly, offering a rapid, receptor‑targeted approach without the need for plasma products.

Icatibant Accord must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

The medication is given by subcutaneous injection, usually into the abdomen or thigh. Administration should be performed by a qualified healthcare professional or a trained patient, following aseptic technique and rotating injection sites to minimize local reactions.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, acute hypotension, and paradoxical angioedema that can affect the airway. Patients should be monitored closely after injection, and any signs of severe allergic response require immediate medical attention.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with severe renal impairment or those receiving medications that significantly increase bradykinin levels, as the risk of adverse reactions may be higher.